On October 1, 2018, Ra Medical Systems, Inc., a manufacturer of laser-based solutions for the treatment of cardiovascular and dermatological diseases, announced the closing of its initial public offering of 4,485,000 shares of common stock, which includes the full exercise of the underwriters' option to purchase 585,000 additional shares of its common stock, at a price to the public of $17 per share. Ra Medical's common stock began trading today on the New York Stock Exchange on September 27, 2018 under the symbol "RMED." Wilson Sonsini Goodrich & Rosati represented Ra Medical Systems in the offering.

Piper Jaffray & Co. and Cantor Fitzgerald & Co. acted as lead joint book-running managers for the offering. SunTrust Robinson Humphrey, Inc. acted as lead manager and Nomura Securities International, Inc. and Maxim Group LLC acted as co-managers for the offering.

The Wilson Sonsini team representing Ra Medical included partners Marty Waters, David Hoffmeister, and Scott McCall and associates Zach Myers, Meg Burton, and Mahnaz Daruwalla.